ProfileGDS5678 / 1429328_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 90% 91% 91% 90% 89% 92% 91% 91% 92% 91% 91% 91% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.1745490
GSM967853U87-EV human glioblastoma xenograft - Control 27.3490490
GSM967854U87-EV human glioblastoma xenograft - Control 37.4675991
GSM967855U87-EV human glioblastoma xenograft - Control 47.50291
GSM967856U87-EV human glioblastoma xenograft - Control 57.292490
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.8188889
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.472492
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.3557891
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.4364591
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.5641292
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.4531291
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.4038991
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.5120291
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.4761591